Literature DB >> 17674314

Interferon- alpha and - beta restrict polyomavirus JC replication in primary human fetal glial cells: implications for progressive multifocal leukoencephalopathy therapy.

Juliene K G Co1, Saguna Verma, Ulziijargal Gurjav, Laarni Sumibcay, Vivek R Nerurkar.   

Abstract

One of the major limitations of highly active antiretroviral therapy is its inability to inhibit the replication of polyomavirus JC (JCV), the etiologic agent of progressive multifocal leukoencephalopathy (PML), an acquired immunodeficiency syndrome-defining illness. We previously demonstrated the induction of interferon (IFN)-stimulated genes (ISGs) by JCV. In the present study, we characterize the specific viral events required to induce ISGs and the potential antiviral effects of type I IFN on JCV replication in human fetal glial cells in the presence and absence of type I IFNs. Productive JCV replication was essential for the induction of the antiviral host response. JCV replication at all steps was significantly inhibited in the presence of IFN, and neutralizing anti-IFN antibody rescued the inhibitory effect of IFN. These results support the use of IFN as an adjunct therapy for patients with PML. Because IFN cannot cross the blood-brain barrier to achieve its direct antiviral effect, intrathecal administration of IFN is warranted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17674314      PMCID: PMC2661426          DOI: 10.1086/520518

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  49 in total

1.  Herpes simplex virus triggers and then disarms a host antiviral response.

Authors:  K L Mossman; P F Macgregor; J J Rozmus; A B Goryachev; A M Edwards; J R Smiley
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Highly active antiretroviral therapy does not improve survival of patients with high JC virus load in the cerebrospinal fluid at progressive multifocal leukoencephalopathy diagnosis.

Authors:  Y Taoufik; J F Delfraissy; J Gasnault
Journal:  AIDS       Date:  2000-04-14       Impact factor: 4.177

3.  The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS.

Authors:  M D Geschwind; R I Skolasky; W S Royal; J C McArthur
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

Review 4.  Challenges for clinical trials to treat progressive multifocal leukoencephalopathy.

Authors:  David B Clifford
Journal:  J Neurovirol       Date:  2003       Impact factor: 2.643

5.  Improvement of SSPE by intrathecal infusion of alpha-IFN.

Authors:  T Kurata; E Matsubara; M Yokoyama; I Nagano; M Shoji; K Abe
Journal:  Neurology       Date:  2004-07-27       Impact factor: 9.910

6.  The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy.

Authors:  A De Luca; M L Giancola; A Ammassari; S Grisetti; M G Paglia; M Gentile; A Cingolani; R Murri; G Liuzzi; A D Monforte; A Antinori
Journal:  J Infect Dis       Date:  2000-08-31       Impact factor: 5.226

7.  The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus.

Authors:  D F Stojdl; N Abraham; S Knowles; R Marius; A Brasey; B D Lichty; E G Brown; N Sonenberg; J C Bell
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

8.  Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy.

Authors:  A De Luca; M L Giancola; A Ammassari; S Grisetti; A Cingolani; M G Paglia; A Govoni; R Murri; L Testa; A D Monforte; A Antinori
Journal:  AIDS       Date:  2000-09-29       Impact factor: 4.177

Review 9.  Antiviral actions of interferons.

Authors:  C E Samuel
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 10.  Novel functions of proteins encoded by viral stress-inducible genes.

Authors:  Saumendra N Sarkar; Ganes C Sen
Journal:  Pharmacol Ther       Date:  2004-09       Impact factor: 12.310

View more
  20 in total

Review 1.  Progressive multifocal leukoencephalopathy: clinical and molecular aspects.

Authors:  Eleonora Tavazzi; Martyn K White; Kamel Khalili
Journal:  Rev Med Virol       Date:  2011-09-21       Impact factor: 6.989

2.  New take on comparative immunology: relevance to immunotherapy.

Authors:  Ena Wang; Adriana Albini; David F Stroncek; Francesco M Marincola
Journal:  Immunotherapy       Date:  2009-05       Impact factor: 4.196

3.  Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinoma.

Authors:  Kelly G Paulson; Andrew Tegeder; Christoph Willmes; Jayasri G Iyer; Olga K Afanasiev; David Schrama; Shinichi Koba; Renee Thibodeau; Kotaro Nagase; William T Simonson; Aaron Seo; David M Koelle; Margaret Madeleine; Shailender Bhatia; Hideki Nakajima; Shigetoshi Sano; James S Hardwick; Mary L Disis; Michele A Cleary; Jürgen C Becker; Paul Nghiem
Journal:  Cancer Immunol Res       Date:  2014-08-12       Impact factor: 11.151

Review 4.  Progressive multifocal leukoencephalopathy and other forms of JC virus disease.

Authors:  Bruce J Brew; Nicholas W S Davies; Paola Cinque; David B Clifford; Avindra Nath
Journal:  Nat Rev Neurol       Date:  2010-12       Impact factor: 42.937

5.  Human polyomavirus JC (JCV) infection of human B lymphocytes: a possible mechanism for JCV transmigration across the blood-brain barrier.

Authors:  Moti L Chapagain; Vivek R Nerurkar
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

6.  Hexadecyloxypropyl-cidofovir (CMX001) suppresses JC virus replication in human fetal brain SVG cell cultures.

Authors:  Zhi-Gang Jiang; Jeffrey Cohen; Leslie J Marshall; Eugene O Major
Journal:  Antimicrob Agents Chemother       Date:  2010-09-07       Impact factor: 5.191

7.  Serotonin receptor 2A blocker (risperidone) has no effect on human polyomavirus JC infection of primary human fetal glial cells.

Authors:  Moti L Chapagain; Laarni Sumibcay; Ulziijargal Gurjav; Pakieli H Kaufusi; Richard E Kast; Vivek R Nerurkar
Journal:  J Neurovirol       Date:  2008-11-12       Impact factor: 2.643

Review 8.  Update on PML: lessons from the HIV uninfected and new insights in pathogenesis and treatment.

Authors:  Elizabeth A Hartman; DeRen Huang
Journal:  Curr HIV/AIDS Rep       Date:  2008-08       Impact factor: 5.071

9.  Interferon beta1-a and selective anti-5HT(2a) receptor antagonists inhibit infection of human glial cells by JC virus.

Authors:  B A O'Hara; W J Atwood
Journal:  Virus Res       Date:  2008-03       Impact factor: 3.303

10.  Disease-modifying drugs for multiple sclerosis and JC virus expression.

Authors:  Craig S Miller; Sidney A Houff; Jason Hopper; Robert J Danaher; Julie A Gurwell; Yushun Lin; Nubia Vega; Joseph R Berger
Journal:  J Neurovirol       Date:  2012-05-15       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.